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Background: The clinical application of cantharidin (CA) is limited by its insolubility, toxicity and short half-life in
circulation. This study aims to achieve a steady and sustained blood concentration–time profile, using solid lipid
nanoparticles (SLNs) as a drug carrier.
Methods: CA-SLNs were prepared by a film dispersion–ultrasonication method. The physiochemical properties
were studied by transmission electron microscopy. In vitro release and in vivo evaluation of CA-SLNs were studied
by GC and GC-MS, while a comparison of the pharmacokinetic properties between CA-SLNs and free CA was
performed in rats.
Results: The mean size, drug content and encapsulation yield of CA-SLNs were 121 nm, 13.28 ± 0.12% and
93.83 ± 0.45%, respectively. The results show that CA-SLNs had a sustained release profile without a burst effect, a
higher bioavailability than free CA after oral administration, and that the relative bioavailability of CA-SLNs to free
CA was 250.8%.
Conclusion: CA-SLNs could improve the solubility and oral bioavailability of CA.Background
Mylabris, the dry body of Mylabris phalerata Pallas or
Mylabris cichorii Linnaeus, is recorded in the People’s
Republic of China Pharmacopoeia as having an antican-
cer effect as well as the biological functions of eliminat-
ing toxic materials, eroding mycosis, eliminating blood
stasis, and dispersing obstructions and lumps [1]. Recent
research [2,3] indicates that cantharidin (CA; 2,3-di-
methyl-7-oxabicyclo [2.2.l] heptane-2.3- dicarboxylic acid
anhydride) is the principal active ingredient amongst the
various compounds present in Mylabris (Figure 1).
Pharmacological studies [4,5] show that CA can inhibit
the growth of various implanted tumors in animal mod-
els by interfering with the metabolism of nucleic acids
and proteins in cancer cells. It has inhibitory effects on
primary hepatoma and other carcinomas, such as uterine
cervix cancer, nasopharyngeal carcinoma, cutaneous
cancer, and leukemia. The therapeutic efficacy of CA in
the treatment of cancer and some refractory diseases had
been demonstrated [6,7].* Correspondence: cuzhu@implad.ac.cn
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reproduction in any medium, provided the orThere are many kinds of Mylabris-based pharmaceut-
ical preparations on the Chinese market, such as com-
pound Mylabris injection (Aidi injection, State Permit
No.Z52020236) and compound Mylabris capsules (State
Permit No.Z19993294; State Permit No.Z200003270;
State Permit No.Z20000427), all of which have proved to
show good anticancer effects.
However, CA causes intense mucous membrane irrita-
tion [8]. It has been reported that mis-ingestion of CA
causes the oral mucous membrane to ulcerate [9]. In
clinical therapeutics, gastrointestinal indisposition is the
main side effect of CA. The clinical use of cantharidin is
limited by its short half-life and toxicity. In our previous
work [10], CA was shown to be a poorly water-soluble
drug with low oral bioavailability (26.7%) in beagle dogs.
In addition, CA is a toxic anticancer drug [11], with a
low lethal dose (30 mg) in humans and a median lethal
dose of about 1 mg/kg [12]. Clinically, CA is adminis-
tered in the dose range of 0.5 – 4 mg/d. It is necessary
to find an efficient drug delivery system to reduce mem-
brane irritation, control in vivo release and improve the
bioavailability of CA.
Our research group has evaluated other preparation
methods to reduce membrane irritation, such as solidal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structure of cantharidin.
Dang and Zhu Chinese Medicine 2013, 8:1 Page 2 of 6
http://www.cmjournal.org/content/8/1/1dispersions [13] and inclusion complexes [14], both of
which could improve bioavailability and reduce irritation
to a certain extent but presented a rapid release and high
maximum serum concentrations (Cmax).
In the pharmaceutical field, the merits of drug delivery
systems in the nanosize range include increased solubility,
reduced toxicity, and improved bioavailability [15]. Solid
lipid nanoparticles (SLNs) are one example of a feasible
nanosized drug carrier system. The particle matrix of a
SLN is composed of solid lipid, which is very attractive for
the controlled release of drugs [14] because drug mobility
in a solid lipid should be considerably lower than in liquid
oil, so that retarded drug release after oral administration
can be achieved. Solid lipid nanoparticles combine the
properties of polymer nanoparticles (a solid matrix for
controlled release) and oil-in-water (o/w) type emulsions.
A number of studies describing the production and physi-
cochemical characterization of particles and associated
drug incorporation and release have been published re-
cently [16-21].
This study aims to improve the oral bioavailability of CA
and control its release profile in vivo using an SLNs formu-
lation, to study the physiochemical properties, and evaluate
the in vitro release and in vivo behaviors of CA-SLNs.Methods
Chemicals and reagents
A standard CA preparation (> 98% purity, 110783–200503)
was purchased from the National Institute for Control of
Pharmaceutical and Biological Products (Beijing, China).
CA used for the preparation was purchased from Nanjing
Zelang Medical Technological Development Co. Ltd in
China (> 98% purity). Glyceryl monostearate was obtained
from Hebei Gaobeidian Chunguang Chemical Reagent
(China). Poloxamer 188 (F-68) was obtained from
Sigma Chemicals (St Louis, MO, USA). Lecithin (Qrs95,Lot: A014989601) was purchased from Shanghai Taiwei
Limited, Shanghai, China.
HPLC-grade methanol was purchased from Fisher
Scientific Co. Ltd. (Dubuque, IA, USA). Absolute alcohol
was of analytical reagent grade (Beijing Shiji, Beijing,
China). All other reagents were of analytical grade (Beijing
Chemicals, Beijing, China).
Instrumental analysis
The exact drug content of the SLNs was determined
using a pump L7100 and a Shimadzu SPD-10AVP UV-
detector (Shimadzu, Japan). An SLC-10AVP (Shimadzu)
equipped with a C-18 reversed-phase chromatographic
column purchased from Dikma (China) (250 × 4.6 mm;
5 μm particle size) was used. The column was main-
tained at 30°C throughout the elution process, using a
mobile phase comprising methanol and water 4:6 (v/v)
at a flow rate of 1 mL/min. The detection wavelength
was 228 nm. The presence of other materials did not
interfere with the analysis of CA.
GC-MS was used to determine the concentration of
CA in plasma. The GC/EI/MS system consisted of a
Trace GC with a Thermo DSQ MSD (Thermo Finnigan,
CA, USA). Samples were injected in splitless mode on a
DB-5MS analytical column (30 m × 0.25 mm i.d. with
0.25 μm film thickness, J. & W. Scientific, USA). The
carrier gas was helium with 99.999% purity at a flow rate
of 1 mL/min. The injector temperature was set at 250°C.
The column temperature started at 60 °C, was held for 1
min and then initially increased at 6°C/min to 220°C and
then to 280°C at 20°C/min. The temperatures of both
the source and MS Quad were at 250°C. The MS was
operated in single ion monitoring (SIM) mode with
electron impact ionization. CA and internal standard
(IS; clofibrate) ion fragments monitored were m/z 128.
Animals
Male Sprague–Dawley rats (SCXK (jing) 2007–0001;
200 – 250 g) were purchased from Vital River Laboratory
Animal Technology Co. Ltd. (Beijing, China) for the ani-
mal experiments. Animals were kept in a normally con-
trolled breeding room with standard laboratory food and
water for one week prior to experiments. The rats were
maintained according to internationally accepted princi-
ples of laboratory animal use and the study was approved
by the Beijing Animal Care Committee. Twelve rats were
randomly divided into two groups for the pharmacoki-
netic study. Another twelve rats were randomly divided
into four groups for the irritation study.
Preparation of the SLNs
Various samples of 2 mg cantharidin, 4 mg lecithin, 10 mg
glyceryl monostearate and 4 mg cholesterol were dissolved
in 10 mL alcohol, and the solution evaporated under
Figure 2 Electron microscope image of CA-SLNs.
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the bottom of the bottle. The residue of the aqueous
phase, containing F-68 (0.5%) and Tween-80 (2%), were
added to allow the film to expand and disperse for 30 min,
and the mixture further dispersed ultrasonically for 60
min to obtain the CA-SLN suspension. On the basis of
optimization for single factors, a central composite design
was used for further optimization. The amounts of CA,
F-68, lecithin, and glyceryl monostearate were used as the
tested variables or independent variables, and encapsula-
tion yield (EY), drug content (DC) as the evaluation
indexes according to the following equations:
EY %ð Þ ¼ WT WF=WTð Þ  100% ð1Þ
DC %ð Þ ¼ WT WF=WTð Þ  100% ð2Þ
where WT and WF are the weights of total drug in SLNs
and free drug in the ultra filtrate after centrifugation,
respectively; and WO is the weight of nanoparticles.
Transmission electron microscopy
SLN dispersions (10 μL) were placed on a copper network
layer on a carbon film. The sample was dried under room
conditions before imaging the SLNs with a transmission
electron microscope (JEM-1400 Transmission Electron
Microscope, JEOL Ltd., Japan), operating at an acceler-
ation voltage of 200 kV.
Determination of mean diameter and surface charge
The mean particle size (z-average) of the SLNs was
measured by photon correlation spectroscopy (Malvern
Mastersizer 2000, U.K.) by a helium-neon laser with a
wavelength of 633 nm. Photon correlations of spectro-
scopic measurements were carried out at a scattering
angle of 90°. A 1:50 dilution of the formulations was made
with double distilled water before measurement. The zeta
potential of CA-SLNs was determined with a zeta poten-
tial instrument (32BIT, Brookhaven, MA, USA).
Drug encapsulation efficiency and drug loading content
determination
Free CA (not loaded within the CA-SLNs) was separated
by an ultrafiltration centrifugation technique (HERAEUS
Labofuge 400R, Thermo Scientific, U.S.A.). 2 mL of SLN
solution loaded CA was added to the centrifugation tech-
nique and centrifuged at 12500 × g for 15 min at 4°C and
the supernatant was then transferred to a clean tube and
filtered with a 0.45 μm membrane. TrionX-100 (0.5 mL,
10%) was added into 2 mL of CA-SLNs colloidal solution
and vortexed for 5 min to obtain the total CA. Free and
total CA concentrations in the CA-SLNs were measured
by HPLC.
The CA-SLNs colloidal solution was withdrawn by
ultracentrifugation and freeze-dried to determine thedrug loading content by accurately weighing the residue.
The EY and DC were then calculated using equations (1)
and (2), respectively.
Mucous membrane irritation experiment
Four groups of three rats had free access to water but
were fasted for 24 h before drug administration and for
4 h after drug administration. All samples including
physiological saline (negative control group), salicylic acid,
free CA and CA-SLN, were dispersed separately in 2 mL
of physiological saline and then administered orally. The
rats were killed via CO2 inhalation. The intact stomach
was removed and cut into pathological sections.
In vitro drug release
CA release from SLNs was performed in phosphate buf-
fered saline (PBS; pH 6.8) by a Franz diffusion cell. A
cellulose membrane was mounted between the donor
and receptor compartments. The donor medium con-
sisted of 2 mL CA-SLNs solution. The receptor medium
consisted of 8 mL of 1.5% PBS in pH 6.8 buffer to main-
tain sink conditions during the experiments. The avail-
able diffusion area between cells was 2.84 cm2. The
stirring rate and temperature were kept at 100 rpm and
37 ± 5°C, respectively. At appropriate intervals, 200 μL
aliquots of the receptor medium were withdrawn and
immediately replaced with an equal volume of fresh buf-
fer. The amount of drug released was determined by
HPLC. All operations were carried out in triplicate.
In vivo administration studies
Two groups of six Sprague–Dawley rats were allowed free
to access to water but were fasted for 24 h before drug
administration and for 6 h after drug administration. CA
A B
Figure 4 Release profiles of free CA and CA in CA-SLNs in PBS (pH 6.8) at 37°C (n = 3).
A B
C D
Figure 3 The profiles of mucous membrane irritation experiments. (A) negative control group (B) positive control group (C) cantharidin
(D) CA-SLNs.
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Figure 5 Representative SIM (m/z = 128) chromatograms of CA and IS. (A) Blank plasma; (B) Typical chromatograms of CA and IS in plasma.
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saline and then administered orally. The doses were
0.1 mg·kg-1 as CA. Blood samples were withdrawn from the
jugular vein of rats at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h after
dosing. Aliquots of 0.2 mL of plasma samples from rats in
a disposable Eppendorf tube, were combined with 200 μL
HCl (6 M), 28 ng of IS (2.8 μg·mL-1) and 2 mL ethyl acet-
ate. After vortexing for 90 s, the tube was centrifuged at
12500 × g for 15 min. The supernatant (0.8 mL) was
transferred to a clean tube and evaporated to dryness
under a stream of nitrogen gas at 30°C. The residue was
dissolved in 50 μL ethyl acetate and then injected into the
GC-MS system for analysis.
The AUC (area under the time-concentration curve)
was calculated using the linear trapezoidal rule (Microsoft
Office Excel 2007, U.S.A.) from zero to the last plasma
concentration. The maximum plasma concentration,
Cmax, and the time at which it occurred, Tmax, were
obtained directly from the actual observed data.Figure 6 The CA plasma drug concentration–time profile for
rats (0.1 mg/kg; n = 5).Results and discussion
Pharmacology studies [3-5] prove that CA can interfere
with the metabolism of nucleic acids and proteins in
cancer cells, significantly inhibiting the growth of vari-
ous implanted tumors in animal models. Although CA
has been shown to possess a strong anticancer effect, its
poor oral absorption and the intense mucous membrane
irritation it can cause may limit its clinical efficacy. In
this study, we used SLNs, as an alternative drug carrier
system to increase absorption, reduce toxicity and im-
prove bioavailability.
SLN properties
The prepared CA-SLNs were round and essentially uni-
form (Figure 2), with a mean diameter of 121 nm. The
zeta potential was −23.09 ± 0.53 mV and they were stable
in solution. An EY of 93.83 ± 0.45% and a DC of 13.28 ±
0.12% (mean ± SD, n = 3) were obtained. The preparative
technology was shown to be reproducible, because the
values of EY and DC were both precisely expressed with a
relative standard deviation of less than 2.5%.
Figure 3 indicates that free CA caused gastrointestinal
mucous membrane irritation (Figure 3C) but the irritation
was relieved after encapsulation in SLNs (Figure 3D). This
may be attributed to the drug entering the HP-β-CD
cavity without coming into direct contact with the gastro-
intestinal mucous membrane.
In vitro dissolution release
Figure 4 indicates that the amount of CA dissolved from
the solid lipid nanoparticles was significantly higher thanTable 1 Pharmacokinetic parameters of CA in two
preparations (n = 5)
Cmax (ng/mL) Tmax (h) AUC0~t (ng/mL)·h Fr (%)
CA 66.21 ± 29.17 2.33 ± 0.56 187.37 ± 76.09 100.0
CA-SLN 106.57 ± 17.56 2.67 ± 0.57 470.01 ± 146.94 250.8
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could be attributed to the nano-size of CA [22].
In vivo administration studies
A sensitive GC-MS method was successfully applied to
determine the plasma concentration of CA in rats after
administration. The time-course concentration data was
analyzed for bioavailability by WinNonLin (version 4.0.
Pharsight Corperation, USA).
Figure 5 shows typical single ion measurement (SIM)
(m/z = 128) chromatograms for CA and clofibrate in
plasma. As shown in Figure 6 and Table 1, after a single
dose of CA (0.1 mg/kg), the Cmax value from CA-SLNs
was higher than that of CA, and a prolonged drug release
was obtained.
Two plasma peaks were observed after the administra-
tion of CA-SLNs. The first peak was attributed to the
presence of free drug and the burst release, while the
second peak was attributed to the controlled release or
potential gut uptake of SLNs. The occurrence of these
two peaks was also reported by Yang et al. [23].
The bioavailability data show that the adsorption of
CA-SLNs was 250.8%, which was higher that of free CA
in vivo, corresponding with the release result determined
in vitro. The different absorption rates between CA and
CA-SLNs could be due to the nanoparticle size and the
influence of the lipid carrier.
Conclusion
CA-SLNs could improve the solubility and oral bioavail-
ability of CA.
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